# Efficacy and Safety of LNP023 Compared With Rituximab in Subjects With Idiopathic Membranous Nephropathy

> **NCT04154787** · PHASE2 · TERMINATED · sponsor: **Novartis Pharmaceuticals** · enrollment: 37 (actual)

## Conditions studied

- Idiopathic Membranous Nephropathy

## Interventions

- **DRUG:** LNP023
- **DRUG:** Rituximab

## Key facts

- **NCT ID:** NCT04154787
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-11-23
- **Primary completion:** 2023-01-20
- **Final completion:** 2023-01-20
- **Target enrollment:** 37 (ACTUAL)
- **Why stopped:** Sponsor decision
- **Last updated:** 2024-10-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04154787

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04154787, "Efficacy and Safety of LNP023 Compared With Rituximab in Subjects With Idiopathic Membranous Nephropathy". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04154787. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*